化疗止吐新药意美(阿瑞匹坦胶囊)疗效怎么样

Yimei (Aprepitant Capsules) is a highly selective substance P neurokinin 1 (NK1) receptor antagonist. It can inhibit acute vomiting and delayed vomiting involving NK1 receptors through antagonizing substance P. It is a neurokinin-1 (NK-1) receptor blocker, which has been gradually promoted clinically in recent years. It can block NK-1 receptors with high selectivity and closely combine with it to inhibit vomiting caused by chemotherapy drugs. It is especially effective in preventing delayed vomiting. Today let’s learn about the efficacy of the new chemotherapy antiemetic drug Yimei (Aprepitant Capsules)?

The therapeutic effects of Yimei (Aprepitant Capsules) are as follows:

In a multicenter, randomized, double-blind controlled clinical trial, patients treated with high-dose (≥70 mg·m) cisplatin experienced highly emetogenic reactions after receiving chemotherapy. The control group received intravenous injection of 20 mg ondansetron on day 1 and oral administration of 20 mg dexamethasone on day 1; 8 mg·d dexamethasone was taken twice on days 2 to 4.

The experimental group received 12 mg dexamethasone and 125 mg aprepitant orally on day 1, 8 mg dexamethasone on days 2-4, and 80 mg·d aprepitant on days 2 and 3.

The effect of the test group was obviously better than that of the control group; taking aprepitant significantly delayed the time to nausea, and also had a good effect on delayed vomiting. Patients in the aprepitant group also had minimal impact on their daily lives due to acute nausea and vomiting caused by chemotherapy;

Aprepitant can significantly and effectively prevent acute nausea and vomiting caused by chemotherapy, and its outstanding advantage is that it can also prevent vomiting and delayed vomiting during chemotherapy.

Yimei’s antiemetic mechanism is:

Yimei can bind to neurokinin-1 receptors, block substance P, and improve symptoms of nausea and vomiting. Yimei also has a high binding rate to protein. Combining this drug with other antiemetics can improve the antiemetic effect and improve patients' treatment compliance.

Yimei Usage and Dosage:

Imeda is a three-day intervention and includes a course of treatment with a corticosteroid and a 5-HT3 antagonist. The recommended dose of Yimei is 125 mg taken orally one hour before chemotherapy on the first day, and 80 mg once daily in the morning on the second and third days.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.